Simpson Curran's most recent trade in Regenxbio Inc was a trade of 233,651 Stock Options (Right to buy) done . Disclosure was reported to the exchange on Jan. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 233,651 | 233,651 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 144,864 | 342,467 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.40 per share. | 02 Jan 2026 | 18,559 | 197,603 (0%) | 0% | 14.4 | 267,250 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.62 per share. | 09 Oct 2025 | 20,811 | 216,162 (0%) | 0% | 12.6 | 262,635 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 29 Sep 2025 | 7,624 | 236,973 (0%) | 0% | 10.0 | 76,469 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 10 Sep 2025 | 7,734 | 244,597 (0%) | 0% | 10.0 | 77,495 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.23 per share. | 01 Jul 2025 | 4,701 | 252,331 (0%) | 0% | 8.2 | 38,689 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 478,606 | 478,606 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 476,606 | 476,606 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 98,912 | 257,032 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 02 Jan 2025 | 11,917 | 158,120 (0%) | 0% | 7.7 | 92,118 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Aug 2024 | 100 | 170,037 (0%) | 0% | 15 | 1,500 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 29 Jul 2024 | 9,648 | 170,137 (0%) | 0% | 15.0 | 145,106 | Common Stock |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 272,189 | 272,189 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Curran Simpson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 56,458 | 179,785 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Simpson Curran | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 61,050 | 61,050 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Simpson Curran | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 38,462 | 123,327 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Simpson Curran | Chief Oper. & Tech. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.95 per share. | 02 Jan 2024 | 8,120 | 84,865 (0%) | 0% | 18.0 | 145,754 | Common Stock |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 67,945 | 92,985 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 52,986 | 52,986 | - | - | Stock Options (Right to buy) | |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.68 per share. | 03 Jan 2023 | 2,076 | 25,040 (0%) | 0% | 22.7 | 47,084 | Common Stock |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 51,100 | 51,100 | - | - | Stock Option (Right to Buy) | |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 10,700 | 27,116 (0%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Curran Simpson | Chief Oper. & Tech. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.70 per share. | 01 Jan 2022 | 1,332 | 16,416 (0%) | 0% | 32.7 | 43,556 | Common Stock |